Docket Number:12A-911101
Inventor:Yijuang Chern, Yi-Chao Lee
IP Status:Issued TWI335327
Abstract:
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion in exon 1 of the Huntingtin (Htt) gene. Htt is widely expressed in the brain and many other tissues. Yet, only specific neuronal populations (including enkephalin-positive striatal neurons) are vulnerable to mutant Htt with expanded CAG repeats. The A2A adenosine receptor (A2A-R), which has been implicated in protection against apoptosis in various cell types, is enriched in Htt/poly(Q)n-sensitive, enkephalin-containing striatal neurons. We have recently shown that an A2A-R selective agonist, CGS21680, effectively improved several major pathological characteristics of HD in an HD mouse model (R6/2). Daily administration of CGS21680 from 7 weeks of age suppresses progressive locomotor deterioration, reverses the increases in striatal choline concentration determined by in vivo proton localized magnetic resonance spectroscopy (1H-MRS), and reduced brain atrophy in HD mice. These results suggest that CGS might be a potential therapeutic drug for the treatment of HD.
Fields of Application:
Potential clinical application for the Huntington's disease
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
IP Status:Issued TWI335327
